Pulse Biosciences Expands Thyroid Nodule Treatment Access via Clayman Center Partnership
Event summary
- Pulse Biosciences partners with Clayman Thyroid Center for commercial and clinical use of nPulse Vybrance System in treating benign thyroid nodules.
- Clayman Thyroid Center becomes the only site in Tampa Bay Area offering nPulse technology for symptomatic benign thyroid nodules.
- Partnership includes real-world outcomes data collection and formal clinical studies to support Vybrance System.
- nPulse Vybrance System provides nonthermal, minimally invasive treatment with same-day discharge for patients.
The big picture
This partnership positions Pulse Biosciences to expand its market reach in the treatment of benign thyroid nodules, leveraging the Clayman Thyroid Center's high-volume patient base and national referral network. The collaboration underscores a broader industry trend toward minimally invasive, nonthermal treatments that reduce surgical risks and improve patient recovery times. The success of this initiative could influence the adoption of nsPFA technology in other medical fields, such as atrial fibrillation and soft tissue ablation.
What we're watching
- Clinical Validation
- Whether the rigorous outcomes data from the partnership will strengthen the Vybrance System's clinical evidence base.
- Market Penetration
- The pace at which the Vybrance System can replace surgical options as the standard of care for benign thyroid nodules.
- Technology Differentiation
- How nsPFA technology's nonthermal approach will compare to existing thermal ablation treatments in patient outcomes and adoption.
Related topics